Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.09. | Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission | 198 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress... ► Artikel lesen | |
06.09. | Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology | 329 | Business Wire | A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of... ► Artikel lesen | |
07.08. | XSpray Pharma AB: Interim Report Second Quarter 2024 | 89 | GlobeNewswire (Europe) | April-June 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -53,620 thousand (-51,402)Earnings per share before dilution amounted to SEK -1.64 (-2.27)Cash flow from... ► Artikel lesen | |
26.07. | XSpray Pharma AB: Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development | 307 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc... ► Artikel lesen | |
09.07. | Xspray Pharma AB: Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose | 304 | Business Wire | Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose.
Xspray Pharma AB (Stockholm/Nasdaq:... ► Artikel lesen | |
08.05. | XSpray Pharma AB: Interim Report First Quarter 2024 | 152 | GlobeNewswire (Europe) | January-March 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -67,781 thousand (-34,827)Earnings per share before dilution amounted to SEK -2.17 (-1.54)Cash flow from... ► Artikel lesen | |
14.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2023 | 300 | GlobeNewswire (Europe) | October-December 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -54,513 thousand (-55,220)Earnings per share before dilution amounted to SEK -1.85 (-2.48)Cash flow... ► Artikel lesen | |
12.02. | FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc - PDUFA Date set to 31 July 2024 | 300 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma's New Drug Application (NDA) for Dasynoc, following... ► Artikel lesen | |
21.11.23 | Xspray Pharma AB: Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage | 426 | Business Wire | XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase... ► Artikel lesen | |
08.11.23 | Xspray Pharma AB: DASYNOC Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL Uptake is Significantly More Impaired than Previously Understood | 443 | Business Wire | DASYNOC (Xspray's low dose, amorphous, non-crystalline, dasatinib) avoids interactions with proton pump inhibitors (PPIs), making it potentially the first and only dasatinib to provide patients... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,730 | +1,74 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
EVOTEC | 7,145 | +0,78 % | Evotec - Das ist die Wende für Anleger!: Reboundchance dank Deal mit Bristol Myers | © Foto: SymbolbildDie Evotec-Aktie gibt gerade ordentlich Gas: Nach einem tiefen Fall von 70 % seit Jahresbeginn hat das Unternehmen nun durch eine Partnerschaft mit dem Pharmariesen Bristol Myers Squibb... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,68 | -0,08 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,120 | +3,08 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
BIONTECH | 102,40 | -0,87 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
NUVALENT | 88,46 | -0,03 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET / 2:30 p.m. CEST
$658.0 million in cash, cash equivalents and marketable... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Is Recursion Pharmaceuticals a Millionaire-Maker Stock? | ||
SUMMIT THERAPEUTICS | 18,860 | +1,45 % | Summit Therapeutics Aktie: Bleiben Sie wachsam! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnete am 26. Oktober 2024 einen bemerkenswerten Kursanstieg von 9,25% auf 21,26 USD. Dieser Aufschwung erfolgt trotz einer herausfordernden... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,100 | -0,38 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
VERA THERAPEUTICS | 43,500 | +7,73 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 47,100 | +5,87 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | ||
TANGO THERAPEUTICS | 5,130 | -5,61 % | TNGX-Aktie erreicht 52-Wochen-Tief bei 5,6 US-Dollar | ||
ATHIRA PHARMA | 0,625 | +45,99 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |